<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0039">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Shannon</surname>
    <given-names>A.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Le</surname>
    <given-names>N. T.-T.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Selisko</surname>
    <given-names>B.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Eydoux</surname>
    <given-names>C.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Alvarez</surname>
    <given-names>K.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Guillemot</surname>
    <given-names>J.-C.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Decroly</surname>
    <given-names>E.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Peersen</surname>
    <given-names>O.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Ferron</surname>
    <given-names>F.</given-names>
   </name>, &amp; 
   <name name-style="western">
    <surname>Canard</surname>
    <given-names>B.</given-names>
   </name>
  </person-group> (
  <year>2020</year>). 
  <article-title>Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites</article-title>. 
  <source>
   <italic>Antiviral Research</italic>
  </source>, 
  <volume>178</volume>, 
  <fpage>104793</fpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104793</pub-id>
  <pub-id pub-id-type="pmid">32283108</pub-id>
 </mixed-citation>
</ref>
